(CTX.TO)MC $9 M / Cash $9 M / Low Float / 5 Marketed Product

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
(CTX.TO)MC $9 M / Cash $9 M / Low Float / 5 Marketed Product

An SI Board Since January 2018

Posts	SubjectMarks	Bans	Symbol
0	0	0	T.CTX

Emcee: BioHero	Type: Moderated

Introduction Market Data Compact

The ultimative most undervalued bio company in canada and usa . Please do your own dd on this undiscovered goldmine and realize the monster potential here .GL

Crescita is a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. In its non-prescription business, Crescita is currently selling five products, including two lines dedicated to medical skincare for pre and post-procedure treatments: Pro-Derm and Alyria; Laboratoire Dr Renaud, its flagship brand sold exclusively to professional aestheticians; Premiology 360, a line of high-end aesthetics products and ISDIN.

Crescita Therapeutics (CTX.TO)

Market Cap: $ 9 Million
Cash: $ 8.8 Million
Kurs: 0.66

Shares Outstanding: 14 Million

Presentation
crescitatherapeutics.com

Crescita targeting $50-million in revenue in 5 years........December 05, 2017
biotuesdays.com

Knight Therapeutics boosts Crescita holdings to 14.9%......2017-10-10
stockwatch.com

"We are excited by Crescita's potential and expect only 'GUD' things to come from this investment," said Jonathan Ross Goodman, chief executive officer of Knight Therapeutics.

CRESCITA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS OF PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PLAQUE PSORIASIS
stockwatch.com

Top Shareholders:

Knight Therapeutics, Inc....2 079 973
Gregory M. C. Orleski ...827 690
Daniel N. Chicoine, CPA...534 784
Serge Verreault, MBA....378 109
John C. London...155 786
David A. Copeland, CPA....57 692
Anthony E. Dobranowski MBA, CPA...52 085
Klaus von Lindeiner-Wildau, PhD....35 200
Alain Dugal....32 150
Wade Hull...28 134

Go to reply# or date (mm/dd/yy):